Ameriprise’s Structure Therapeutics GPCR Stock Holding History

Ameriprise’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Sell	219,516 -66,002	-23%	-$4.52M	﹤0.01%	1885
2025 Q4	$19.9M	Sell	285,518 -938,626	-77%	-$38.3M	﹤0.01%	1420
2025 Q3	$34.3M	Sell	1,224,144 -364,054	-23%	-$7.25M	0.01%	1087
2025 Q2	$32.9M	Buy	1,588,198 +106,389	+7%	+$2.34M	0.01%	1083
2025 Q1	$25.7M	Buy	1,481,809 +61,757	+4%	+$1.51M	0.01%	1167
2024 Q4	$38.5M	Buy	1,420,052 +322,601	+29%	+$11.4M	0.01%	974
2024 Q3	$48.2M	Buy	1,097,451 +690,607	+170%	+$26.7M	0.01%	871
2024 Q2	$16M	Buy	406,844 +316,187	+349%	+$13M	﹤0.01%	1412
2024 Q1	$3.89M	Buy	90,657 +27,900	+44%	+$1.18M	﹤0.01%	2520
2023 Q4	$2.56M	Buy	+62,757	New	+$3.6M	﹤0.01%	2754

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ameriprise's GPCR Position: Q1 2026 in Review

Ameriprise reduced its Structure Therapeutics (GPCR) stake by 23% in Q1 2026, selling an estimated $4.52M and leaving 219,516 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Ameriprise first reported a position in GPCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $48.2M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Ameriprise held 219,516 shares of Structure Therapeutics worth $10.6M as of Q1 2026.
Ameriprise sold 66,002 Structure Therapeutics shares in Q1 2026, an estimated $4.52M.
Structure Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1885 holding.
Ameriprise first reported a position in Structure Therapeutics in Q4 2023 and has held it in 10 quarters since.
Ameriprise's Structure Therapeutics position peaked at $48.2M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.